(NXTD)New DreamTrips Smart Card Developed by NXT-ID to Over 22,000 Members

MELBOURNE, Florida, January 19, 2016 /PRNewswire/ —

NXT-ID, Inc. (NASDAQ:NXTD) (“NXT-ID” or the “Company”), a company focused on the growing mobile commerce market, reports the new smart card being developed for WorldVentures Vacation Club Members was introduced to an enthusiastic audience at their annual UNITED conference, held in Orlando, Fla. Jan. 15-17^th .

On Jan. 4, WorldVentures and NXT-ID, Inc. announced a strategic alliance to develop a proprietary new wireless smart card for its Members, based on NXT-ID’s Wocket® smart wallet technology.

According to WorldVentures, “Over 22,000 Independent Representatives came together to celebrate past successes, look ahead to the next decade with innovative new technologies and travel products, and give back to the Orlando community.”

During the conference, WorldVentures introduced the DreamTrips smart card, being developed exclusively for them by NXT-ID, that will be customized with additional technologies and wireless features, such as the ability to seamlessly integrate with the WorldVentures DreamTrips App to wirelessly check in and earn loyalty points towards free DreamTrips vacations at select restaurants.

WorldVentures currently has approximately 500,000 DreamTrips Members, with as many as 80,000 new Members joining every month. The vision of WorldVentures’ executive team is to make the smart card available to every existing Member, and provide a Member kit to every new Member that includes the smart card purchased from NXT-ID.

In the presentation to Members, it was demonstrated how the new smart card, just like the Wocket card designed to replace all the cards in your wallet, the new DreamTrips card will make travel and vacationing simpler and more secure.

David Tunnell, Executive Vice-President and Chief Technology Officer for NXT-ID was invited onstage during the smart card presentation. He said, “We received an overwhelmingly enthusiastic and positive reception at the convention. It was quite an experience being in front of tens of thousands of people and witness the support for our smartcard technology.”

Video:  WorldVentures conference clip: https://youtu.be/I1Q99GMktr4

About WorldVentures

WorldVentures Marketing, LLC is the leading international direct seller of vacation club memberships and helps people achieve more fun, freedom and fulfillment by offering DreamTrips™ memberships, which include premium vacations at reduced prices. WorldVentures is a privately held company based in Plano, Texas, with active Representatives and Members in 28 countries. For more information, please visit http://www.worldventures.com.

About NXT- ID Inc. – Mobile Security for a Mobile World

NXT-ID, Inc.’s innovative MobileBio® solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio® suite of solutions that secure consumers’ mobile platforms led by Wocket®; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. http://www.wocketwallet.com/

NXT-ID’s wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification and has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/

Product images are available for media at: http://press.nxt-id.com

Wocket® is the smartest wallet you’ll ever own. Designed to protect your identity and replace your old wallet, simply save your cards into Wocket once and they are immediately secured. You can choose a card from the touch screen and Wocket programs its single, smart card (Wocket Card) or uses its NFC touch to pay technology to match your selection. Your Wocket can be used virtually anywhere that credit cards are accepted today. Wocket can also display a variety of barcodes.

All your credit, debit, loyalty, gift, ID, membership, insurance, medical information, passwords, and virtually any other information can be protected on Wocket®.

Forward-Looking Statements for NXT-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

NXT- ID Inc Contact:
Corporate info: info@nxt-id.com

Media:
D. Van Zant
1-800-665-0411
press@nxt-id.com

(ACOR) to Acquire (BITI)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it entered into an agreement to acquire Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) for €23.5680 per ADS in cash, or the equivalent of $25.60 per ADS based on an exchange rate of 1.0864 U.S. dollars to euros, which values Biotie at approximately $363 million.

Acorda will obtain worldwide rights to tozadenant, an oral adenosine A_2a receptor antagonist currently in Phase 3 development in Parkinson’s disease (PD). In a Phase 2b clinical trial, tozadenant reduced average daily OFF time as an adjunct to treatment regimens including levodopa/carbidopa.

Further expanding its Parkinson’s pipeline, Acorda will also obtain global rights to SYN120, an oral, 5-HT₆/5-HT_2A dual receptor antagonist for Parkinson’s-related dementia, in Phase 2 development with support from the Michael J. Fox Foundation.

“Our acquisition of Biotie positions Acorda as a leader in Parkinson’s disease therapeutic development, with three clinical-stage compounds that have the potential to improve the lives of people with Parkinson’s. Tozadenant, Biotie’s most advanced clinical program, is a promising therapy being developed to reduce daily OFF time,” said Ron Cohen, M.D., Acorda’s President and CEO. “Adenosine A_2a receptor antagonists may be the first new class of drug approved for the treatment of Parkinson’s in the U.S. in over 20 years. Approximately 350,000 people with Parkinson’s in the U.S. experience OFF periods, and if approved, tozadenant could provide a much needed treatment option.”

Dr. Cohen added, “Tozadenant is a compelling opportunity with potential market exclusivity to 2030. The Phase 2 data were highly statistically significant and clinically meaningful. We are targeting an NDA filing by the end of 2018.”

Tozadenant is an orally administered, potent and selective antagonist of the adenosine A_2A receptor. Adenosine is a neurotransmitter, one of the naturally occurring chemical messengers that transmit signals between neurons in the brain. The A_2a receptor is one of the types of chemical receptors on neurons that mediate the adenosine signal. This receptor is expressed particularly in the motor control part of the brain that is affected in people with Parkinson’s. Activation of the A_2a receptor has effects in the brain that antagonize the action of another neurotransmitter, dopamine, in this brain region. A loss of dopamine input is a central mechanism of PD and treatment with levodopa is designed to restore more normal dopamine levels in the brain. Blocking of A_2a receptors with tozadenant serves to dampen the antagonistic effect of adenosine on dopamine and thereby promotes motor function.

A 420-patient Phase 2b trial published in Lancet Neurology compared four different doses of tozadenant to placebo, using patient diaries to record OFF time in patients on a stabilized regimen of levodopa and up to three additional medications. OFF time is characterized by a re-emergence of PD motor symptoms, such as impaired ability to move, muscle stiffness and tremor. The average daily OFF time for individuals receiving tozadenant at the 120 mg dose decreased by 1.9 hours, or 1.1 hours relative to placebo (5.9 hours per day at baseline to 4.0 hours at twelve weeks). Notably, this improvement in OFF time was not associated with significant increases in troublesome dyskinesia for doses being studied in the ongoing Phase 3 program (60mg and 120 mg).

The most common adverse events in the this trial for the 60 mg and 120 mg dose groups were: dyskinesia (14% in the 60 mg group, 16% in the 120 mg twice-daily group, 8% placebo group); nausea (6% in the 60 mg group, 9% in the 120 mg twice-daily group, 4% placebo group); and dizziness (5% in the 60 mg group, 5% in the 120 mg twice-daily group, 1% placebo group). Serious adverse events were reported in 13 patients (placebo – 3; tozadenant: 60 mg – 1, 120 mg – 3, 180 mg – 2, 240 mg – 4). There were six deaths in this study (placebo – 0; tozadenant: 60 mg -1, 120 mg – 0, 180 mg – 2, 240 mg – 3). Neither the drug safety monitoring board (DSMB) nor a second panel of experts who reviewed the data identified a relationship between treatment with tozadenant and serious adverse events or deaths.

Biotie is headquartered in Turku, Finland, with clinical operations based in South San Francisco, CA. Following the close of the acquisition, Acorda plans to maintain the South San Francisco location and retain Biotie staff at that site. Acorda is considering the long-term future of the Turku facility. With this addition, Acorda will have operations in three major U.S. biotechnology centers: New York, Boston and San Francisco.

Mr. William M. Burns, Chairman of the Board of Biotie, commented, “We have carefully assessed the terms and conditions of the offer and believe that it is an attractive offer to shareholders that recognizes the strategic value of Biotie.”

Mr. Burns continued, “With the shared mission to improve the lives of patients with neurological diseases, this transaction will allow Acorda and Biotie to bring together their expertise and resources in order to fully maximize the potential of tozadenant, an A_2a receptor antagonist in Phase 3 for Parkinson’s disease, and SYN120 a dual 5-HT₆/5-HT_2A receptor antagonist in Phase 2 for cognitive and psychotic disorders, and to bring new medicines to patients. We are excited about this offer for our shareholders, the Biotie team and for patients.”

The acquisition also includes two other assets: BTT1023, a fully human monoclonal antibody in Phase 2 development for treatment of primary sclerosing cholangitis (PSC), a chronic liver disease; and double-digit royalties from sales of Selincro^®, a European Medicines Agency (EMA)-approved therapy for reduction in alcohol consumption marketed by H. Lundbeck A/S in multiple European countries.

The $363 million all-cash tender offer in Finland and the United States is unanimously recommended by Biotie’s Board of Directors. The transaction was also unanimously approved by Acorda’s Board of Directors. Subject to customary closing conditions, the tender offer is expected to be completed in the first or second quarter of 2016, and the acquisition is expected to be completed in the third quarter of 2016.

Financing Transactions

Concurrently with the announcement of the Biotie transaction, Acorda announced two separate financing transactions.

Acorda has agreed to issue $75 million of common stock (the “Shares”) in a private placement transaction exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). Acorda intends to use the net proceeds from the issuance of the Shares to fund, in part, the acquisition of Biotie described above. The issuance of the Shares is not contingent upon the consummation of the acquisition of Biotie or the terms of the acquisition. If the acquisition of Biotie is not consummated for any reason, the Company will use all of the net proceeds from the issuance of the Shares for general corporate purposes. The closing of the private placement is expected to occur in January 2016 and is subject to customary closing conditions.

Acorda also received a commitment from JPMorgan Chase, N.A. for an asset-based loan facility for up to $60 million. The closing of this transaction is expected to occur within six weeks and is subject to customary closing conditions.

The Shares will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from registration requirements or a transaction not subject to the registration requirements of the Securities Act or any state securities laws.

This press release is issued pursuant to Rule 135(c) under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful.

Acorda had $353 million in cash at year-end 2015 (unaudited). Following the close of the transaction, the Company expects the net proceeds from the common stock issuance, together with the availability under the asset-based credit facility, to be sufficient to fund ongoing operations.

Lazard, MTS Health Partners and J.P. Morgan Securities LLC served as financial advisors, and Kirkland & Ellis, Roschier, Covington & Burling LLP and Jones Day LLP served as legal advisors to Acorda in connection with this transaction. Guggenheim Securities served as Biotie Therapies’ financial advisors, and Davis Polk & Wardwell LLP and Hannes Snellman Attorneys Ltd. served as Biotie’s legal advisors.

Webcast and Conference Call

Ron Cohen, President and Chief Executive Officer, and Michael Rogers, Chief Financial Officer, will host a conference call today at 8:00 a.m. ET.

To participate in the conference call, please dial 855-542-4209 (domestic) or 412-455-6054 (international) and reference the access code 31734527. The presentation will be available via a live webcast on the Investor section of www.acorda.com.

A replay of the call will be available from 11:00 a.m. ET on January 19, 2016 until midnight on January 26, 2016. To access the replay, please dial 855-859-2056 (domestic) or 404-537-3406 (international) and reference the access code 31734527. The archived webcast will be available for 30 days in the Investor Relations section of the Acorda website at www.acorda.com.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including multiple sclerosis, Parkinson’s disease, post-stroke walking deficits, epilepsy and migraine. Acorda markets three FDA-approved therapies, including AMPYRA^® (dalfampridine) Extended Release Tablets, 10 mg.

About Biotie Therapies

Biotie Therapies is a biopharmaceutical company primarily focused on developing therapeutics for central nervous system disorders. Its pipeline includes product candidates designed to address unmet medical needs in Parkinson’s disease and related dementia, other neurodegenerative indications and primary sclerosing cholangitis, an orphan fibrotic liver disease. In addition, Biotie has successfully developed a product for alcohol dependence that is being commercialized by Lundbeck and is a source of further potential milestone payments and ongoing royalties.

Forward-Looking Statement

This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including the ability to complete the Biotie transaction on a timely basis or at all; the ability to realize the benefits anticipated to be realized by the Biotie transaction and the Civitas transaction; the ability to successfully integrate Biotie’s operations and Civitas’ operations, respectively, into our operations; we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms; our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including CVT-301, Plumiaz, or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market CVT-301, Plumiaz, or any other products under development; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen in connection therewith; competition; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies. In addition, the compounds being acquired from Biotie are subject to all the risks inherent in the drug development process, and there can be no assurance that these compounds will receive regulatory approval or be commercially successful. These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.

Additional Information

The tender offer described in this release has not yet commenced, and this release is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, we will file, or will cause a new wholly owned subsidiary to file, with the SEC a tender offer statement on Schedule TO. Investors and holders of Biotie Equity Interests are strongly advised to read the tender offer statement (including an offer to purchase, letter of transmittal and related tender offer documents) and the related solicitation/recommendation statement on Schedule 14D-9 that will be filed by Biotie with the SEC, because they will contain important information. These documents will be available at no charge on the SEC’s website at www.sec.gov upon the commencement of the tender offer. In addition, a copy of the offer to purchase, letter of transmittal and other related tender offer documents (once they become available) may be obtained free of charge by directing a request to us at www.acorda.com or Office of the Corporate Secretary, 420 Saw Mill River Road, Ardsley, New York 10502.

In addition to the offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, we file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by us at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. our filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

THE OFFER WILL NOT BE MADE DIRECTLY OR INDIRECTLY IN ANY JURISDICTION WHERE EITHER AN OFFER OR PARTICIPATION THEREIN IS PROHIBITED BY APPLICABLE LAW OR WHERE ANY TENDER OFFER DOCUMENT OR REGISTRATION OR OTHER REQUIREMENTS WOULD APPLY IN ADDITION TO THOSE UNDERTAKEN IN FINLAND AND THE UNITED STATES.

IN ADDITION, THE TENDER OFFER DOCUMENTS, THIS RELEASE AND RELATED MATERIALS AND ACCEPTANCE FORMS WILL NOT AND MAY NOT BE DISTRIBUTED, FORWARDED OR TRANSMITTED INTO OR FROM ANY JURISDICTION WHERE PROHIBITED BY APPLICABLE LAW. IN PARTICULAR, THE TENDER OFFER IS NOT BEING MADE, DIRECTLY OR INDIRECTLY, IN OR INTO, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG. THE TENDER OFFER CANNOT BE ACCEPTED BY ANY SUCH USE, MEANS OR INSTRUMENTALITY OR FROM WITHIN CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG.

Acorda Therapeutics
Investors
Felicia Vonella, 914-326-5146
fvonella@acorda.com
or
Media
Jeff Macdonald, 914-326-5232
jmacdonald@acorda.com

(CNCK) Issues Letter to Shareholders on Status of Company, Future Uplisting

(AMRS) Launches Pathways Program

Provides Partners With Low-Cost, Low-Risk Opportunity to Access Transformational Technology Platform

EMERYVILLE, Calif., Jan. 15, 2016  — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced the availability of its Pathways Program, a program that provides partners a low-cost, low-risk opportunity to access Amyris’s industry-leading synthetic biology technology. Through the Pathways Program, partners can, with a small initial investment, sponsor and secure a molecule they are interested in having Amyris produce using the next-generation tools and technologies being developed through the company’s recently announced technology investment agreement with the Defense Advanced Research Projects Agency (DARPA). Amyris expects the powerful combination of its existing core technology and bioengineering advancements enabled by its project with DARPA will significantly reduce the time and cost of bringing new molecules to market using industrial biotechnology. The Pathways Program allows partners to access these latest developments and explore bio-synthetic production opportunities with minimal risk and commitment.

Provides Partners a De-Risked Opportunity to Explore Development of New Molecules with a Leader in Synthetic Biology

The Pathways Program provides partners with a de-risked opportunity to use Amyris’s expert capabilities and advanced tools and methodologies for the construction of organisms that convert sugar to the partner’s target molecule. The successful completion of the organism engineering potentially provides a new mode of production with secure stable supply from a renewable resource.

In essence, this program opens up Amyris’s advanced technology platform and leading capabilities to researchers and companies wishing to determine the viability of biological production of target molecules at a lower cost and with minimized risk.

“Our Pathways Program provides partners with a unique and advantaged opportunity to access cutting-edge technologies that are at the forefront of bioengineering to explore the development of new materials with little upfront risk,” said John Melo, President & CEO at Amryis. “Our mission is to accelerate the transition to a world that uses sustainably sourced bio-materials and we believe that making our technology more accessible removes a key barrier to making lower cost, higher performing products for a healthier planet. We have now created several $100-million-dollar supply opportunities for our renewable farnesene technology and expect many more building blocks, like farnesene, to come from opening our platform to the world.”

For partners interested in accessing faster, lower cost to market for sustainable biochemistry please contact Cindy Bryant, Amyris’s Senior Vice President Corporate Development & Collaborations at 510-450-0761 ext. 468.

About Amyris

Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as Amyris’s ability to offer molecule development services at low risk and low cost to potential partners and the ability of Amyris technology, existing and under development, to significantly reduce the time and cost of bringing new molecules to market using industrial biotechnology), that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on November 9, 2015. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris and the Amyris logo are registered trademarks of Amyris, Inc. All other trademarks are the property of their respective owners.

Contacts:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
investor@amyris.com
pr@amyris.com

(TSEM) to Take Part in the Drexel Management Call Series, January 19, 2016

MIGDAL HAEMEK, Israel, Jan. 15, 2016  — TowerJazz (NASDAQ: TSEM), the global specialty foundry leader, today announced that its Chief Executive Officer, Russell Ellwanger, CFO, Oren Shirazi and Head of Investor and Public Relations, Noit Levi, will be attending and taking part in the Drexel Hamilton quarterly management call series. In addition to the Drexel analyst’s questions, there will be an opportunity for investors to ask management questions directly.

The call will take place at 10:00 am EST on Tuesday, January 19.

To participate please dial: 1 719 325 2630; with conference key 401593.

About TowerJazz

Tower Semiconductor Ltd. (NASDAQ: TSEM, TASE: TSEM), its fully owned U.S. subsidiary Jazz Semiconductor, Inc. and its fully owned Japanese subsidiary TowerJazz Japan, Ltd., operate collectively under the brand name TowerJazz, the global specialty foundry leader. TowerJazz manufactures integrated circuits, offering a broad range of customizable process technologies including: SiGe, BiCMOS, Mixed-Signal/CMOS, RF CMOS, CMOS Image Sensor, integrated Power Management (BCD & 700V), and MEMS capabilities. TowerJazz also provides a world-class design enablement platform for a quick and accurate design cycle as well as Transfer Optimization and development Process Services (TOPS) to IDMs and fabless companies that need to expand capacity.

To provide multi-fab sourcing and extended capacity for its customers, TowerJazz operates two manufacturing facilities in Israel (150mm & 200mm), one in the U.S. (200mm), and four in Japan (200mm & 300mm). Three of the Japan fabs are available through TowerJazz Panasonic Semiconductor Company (TPSCo), established with Panasonic Corporation of which TowerJazz has the majority holding. Through TPSCo, TowerJazz offers leading edge 45nm CMOS, 65nm RF CMOS and 65nm 1.12um pixel technologies. For more information, please visit: www.towerjazz.com.

CONTACT: Tower Semiconductor
         Noit Levi, +972 4 604 7066
         Noit.levi@towerjazz.com

         GK Investor Relations
         Kenny Green, (646) 201 9246
         towerjazz@gkir.com

(FORK) to Supply Leading U.S. Distributor Bunzl’s Western Region

ALLENTOWN, Pa., and TAIZHOU, China, Jan. 15, 2016  — Fuling Global Inc. (NASDAQ: FORK) (“Fuling Global” or the “Company”), a specialized producer and distributor of environmentally-friendly plastic serviceware, with precision manufacturing facilities in both the U.S. and China, today announced that its U.S. subsidiary Domo Industry Inc. (“Domo”) has agreed to supply disposable cutlery to the western region of Bunzl Distribution USA Inc. (“Bunzl USA”). Bunzl USA is a leading supplier of a wide range of products serving the food industry, including outsourced food packaging, disposable supplies, and cleaning and safety products to food processors, supermarkets, non-food retailers, convenience stores and other users. Bunzl USA is the largest subsidiary of Bunzl plc, an international distribution and outsourcing group listed on the London Stock Exchange.

Starting from this month, Domo will begin supplying disposable plastic serviceware, including cutlery, polyethylene terephthalate (“PET”) cups, and calcium polypropylene (“PP”) hinged containers, to the western region of Bunzl USA’s R3 Redistribution Division (“R3”). Headquartered in Chicago, IL, R3 services the U.S., Canada, Mexico and Puerto Rico markets with over 74 shipping facilities, 2,600 professionals and one of largest trucking fleets in North America, which features more than 450 tractors and 650 trailers.

Mr. Lee Yu, Vice President of Domo, commented, “We have been discussing cooperation with Bunzl USA for some time. Our reputation as a quality supplier in the U.S. market, the launch of our Allentown manufacturing facility and Fuling’s recent NASDAQ listing helped us reach this significant relationship with Bunzl USA. Domo will begin supplying disposable cutlery to R3’s Los Angeles and Seattle branches immediately, with PET cups and calcium PP hinged containers to follow. We also hope to supply straws produced at Fuling Global’s Allentown, PA facility and other products to R3 in the future.”

“We are excited about the opportunities this new cooperation with Bunzl USA provides Fuling,” said Mr. Xinfu Hu, Chief Executive Officer of Fuling Global. “With its extensive network of warehouses, distribution centers and sizable trucking fleet, Bunzl USA gives us an excellent platform to further penetrate the U.S. market. Kudos to the Domo Team and we look forward to continuing to grow this relationship for years to come.”

About Bunzl Distribution USA, Inc.

Bunzl Distribution USA, Inc. (“Bunzl USA”) supplies a range of products including outsourced food packaging, disposable supplies, and cleaning and safety products to food processors, supermarkets, non-food retailers, convenience stores and other users. Based in St. Louis, Missouri, Bunzl USA is the largest division of Bunzl plc, an international distribution and outsourcing group listed on the London Stock Exchange. Bunzl USA owns and operates more than 100 warehouses that serve all 50 states and Puerto Rico, as well as Canada, the Caribbean and parts of Mexico. With more than 4,000 employees and 400,000-plus supply items, Bunzl USA is regarded as one of the leading suppliers in North America.

About Fuling Global Inc.

Fuling Global Inc. (“Fuling Global”) is a specialized producer and distributor of environmentally friendly plastic serviceware, with precision manufacturing facilities in both the U.S. and China. The Company’s plastic serviceware products include disposable cutlery, drinking straws, cups, plates and other plastic products and are used by more than one hundred customers primarily from the U.S. and Europe, including Subway, Wendy’s, Burger King, KFC (China only), Walmart, McKesson, and Woolworths. More information about the Company can be found at: http://ir.fulingglobal.com/.

Forward-Looking Statements

This press release contains information about Fuling Global’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of software and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Fuling Global encourages you to review other factors that may affect its future results in Fuling Global’s registration statement and in its other filings with the Securities and Exchange Commission.

For more information, please contact:

At the Company:
Gilbert Lee, CFO
Email: ir@fulingplasticusa.com
Phone: +1-610-366-8070×1835
Web: http://ir.fulingglobal.com/

Investor Relations:
Tina Xiao
Weitian Group LLC
Email: fork@weitian-ir.com
Phone: +1-917-609-0333

(DGLY) USPTO Confirms Validity of Revolutionary ‘292 Patent on Body Camera Tech

Digital Ally Files Lawsuit Against TASER International, Inc. for Willful Infringement and Seeks an Injunction Preventing TASER From Selling Its Axon Body Camera Product Line

(NVLS) Announces FDA Orphan Drug Designation for N91115 in Cystic Fibrosis

Designation Marks Important Milestone in the Development and Regulatory Pathway for the First CFTR Stabilizer

BOULDER, Colo., Jan. 15, 2016  — Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis (“CF”), today announced the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to the Company’s lead investigational drug, N91115, a novel stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

“The Orphan Drug Designation represents an important milestone in the development and regulatory strategy for N91115 and underscores the unmet need that remains in treating CF,” said Jon Congleton, president and chief executive officer of Nivalis. “We look forward to the continued clinical advancement of this first-in-class CFTR stabilizer, a new approach to modulating the defective CFTR protein.”

The Company recently initiated a Phase 2, 12-week, double-blind, randomized, placebo-controlled, parallel group study to investigate the efficacy and safety of N91115 in 135 adult patients with CF who are homozygous for the F508del-CFTR mutation and being treated with Orkambi™. Results of this study are planned to be reported in the second half of 2016. N91115 works through a novel mechanism of action called S-nitrosoglutathione reductase (GSNOR) inhibition that is presumed to modulate the unstable and defective CFTR protein responsible for CF.

The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose or prevent diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees.

The Company will also seek Fast Track status for its development program with N91115. A Fast Track designation enables more frequent interactions with the FDA to expedite the development and review process for drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

For more information on the Phase 2 study, please visit ClinicalTrials.gov and reference Identifier NCT02589236.

About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with cystic fibrosis (CF). In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

About N91115
CF is a life-shortening genetic disease that affects an estimated 70,000 people worldwide, predominately in the United States and Europe, according to the Cystic Fibrosis Foundation (www.cff.org). CF is characterized by a defect in the chloride channel known as the “cystic fibrosis transmembrane conductance regulator,” or CFTR, and is caused by mutations in the CFTR gene. N91115 works through a novel mechanism of action called GSNOR inhibition that is presumed to modulate the unstable and defective CFTR protein responsible for CF. GSNOR inhibition restores GSNO levels thereby modifying the chaperones responsible for CFTR protein degradation. This stabilizing effect increases and prolongs the function of the CFTR chloride channel and leads to an increase in net chloride secretion. Nivalis discovered and owns exclusive rights to N91115 in the United States (U.S.) and all other major markets, including U.S. composition of matter patent protection until at least 2031.

Nivalis Therapeutics has completed clinical studies with N91115, including a Phase 1a dose-escalation safety study in healthy volunteers, and a Phase 1b safety study in people with CF who have two copies of the F508del mutation. In preclinical studies, N91115 has been shown to increase the function of F508del-CFTR, the mutant protein that is estimated to be present in approximately 86 percent of people with CF in the United States and Europe.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nivalis’ development plans and potential opportunities and expectations that early stage clinical trials are indicative of later stage clinical trial results or will result an approved drug. These forward-looking statements are based on management’s current expectations of future events and involve substantial risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the risk that the timing of site initiation and patient enrollment for our clinical trials may take longer than expected, delays in the timing of regulatory filings and approvals, delays in the commercialization or availability of lumacaftor/ivacaftor, and other matters that could affect the completion of the clinical development and commercial potential of the company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Nivalis’ business in general, see the risk factors contained in the company’s prospectus filed with the Securities and Exchange Commission on June 17, 2015, in the company’s most recent quarterly report on Form 10-Q and in its other reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of this release, and Nivalis undertakes no duty to update or revise this information unless required by law. 

Contacts:

Investor Relations 
John Graziano
1-646-378-2942
jgraziano@troutgroup.com

Media Relations 
Lindsay Rocco
1-862-596-1304
lrocco@elixirhealthpr.com

(SYUT) Announces Receipt of Preliminary Non-Binding “Going Private” Proposal

QINGDAO, China and ROCKVILLE, Md., Jan. 15, 2016  — Synutra International, Inc. (Nasdaq: SYUT), (“Synutra” or the “Company”), which owns subsidiaries in China that produce, distribute and sell nutritional products for infants, children and adults, today announced that its board of directors (the “Board”) has received a non-binding proposal letter, dated January 14, 2016, from Mr. Liang Zhang (“Mr. Zhang”), Chairman and chief executive officer of Synutra, and an affiliated entity of his (together with Mr. Zhang, the “Buyer Group”), proposing a “going-private” transaction (the “Transaction”) to acquire all of the outstanding common stock (the “Shares”) of the Company not already owned by the Buyer Group for US$5.91 in cash per Share, subject to certain conditions, which represents a premium of approximately 63% to the closing price of the Company’s Shares on January 13, 2016, and a premium of approximately 30% to the volume-weighted average closing price of the Company’s Shares during the last 20 trading days.

According to the proposal letter, the Buyer Group intends to fund the consideration payable in the Transaction with a combination of equity capital and third party debt, and rollover equity in the Company. A copy of the proposal letter is attached as Annex A to this press release.

The Board intends to form a special committee consisting of independent directors to consider this proposal.

The Board cautions the Company’s shareholders and others considering trading in its securities that the Board just received the non-binding proposal letter from the Buyer Group and no decisions have been made with respect to the Company’s response to the Transaction. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to this or any other transaction, except as required under applicable law.

About Synutra International, Inc.

Synutra International, Inc. (Nasdaq: SYUT) is a leading infant formula company in China. It principally produces, markets and sells its products through its operating subsidiaries under the “Shengyuan” or “Synutra” name, together with other complementary brands. It focuses on selling premium infant formula products, which are supplemented by more affordable infant formulas targeting the mass market as well as other nutritional products and ingredients. It sells its products through an extensive nationwide sales and distribution network covering all provinces and provincial-level municipalities in mainland China. As of September 30, 2015, this network comprised over 770 independent distributors and over 290 independent sub-distributors who sell Synutra products in approximately 22,800 retail outlets.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on our current expectations, assumptions, estimates and projections about Synutra and its industry. All statements other than statements of historical fact in this release are forward-looking statements. In some cases, these forward-looking statements can be identified by words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “is/are likely to,” “may,” “plan,” “should,” “will,” “aim,” “potential,” “continue,” or other similar expressions. The forward-looking statements included in this press release relate to, among others, Synutra’s goals and strategies; its future business development, financial condition and results of operations, particularly the progress on the new drying facility project in France; the expected growth of the nutritional products and infant formula markets in China; market acceptance of Synutra’s products; the safety and quality of Synutra’s products; Synutra’s expectations regarding demand for its products; Synutra’s ability to stay abreast of market trends and technological advances; competition in the infant formula industry in China; PRC governmental policies and regulations relating to the nutritional products and infant formula industries and our ability to meet governmental requirements, and general economic and business conditions in China. These forward-looking statements involve various risks and uncertainties. Although Synutra believes that the expectations expressed in these forward-looking statements are reasonable, these expectations may turn out to be incorrect. Synutra’s actual results could be materially different from the expectations. Important risks and factors that could cause actual results to be materially different from expectations are generally set forth in Synutra’s filings with the Securities and Exchange Commission. The forward-looking statements are made as of the date of this press release. Synutra undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Annex A

January 14, 2016

The Board of Directors
Synutra International, Inc.
2275 Research Blvd., Suite 500
Rockville, Maryland 20850
United States

Dear Members of the Board of Directors,

Mr. Liang Zhang (“Mr. Zhang“), chairman of the board of directors of Synutra International, Inc. (the “Company“), and Beams Power Investment Limited (together with Mr. Zhang, the “Buyer Parties“), an investment vehicle wholly owned by Mr. Zhang’s wife, Ms. Xiuqing Meng, are pleased to submit this preliminary non-binding proposal to acquire all of the outstanding shares of common stock (the “Shares“) of the Company that are not already beneficially owned by the Buyer Parties in a going private transaction (the “Transaction“).

We believe that our proposal of US$5.91 per Share in cash provides a very attractive opportunity to the stockholders of the Company. This price represents a premium of approximately 63% to the closing price of the Company’s Shares on January 13, 2016 and a premium of approximately 30% to the volume-weighted average closing price of the Company’s Shares during the last 20 trading days.

The terms and conditions upon which we are prepared to pursue the Transaction are set forth below.  We are confident in our ability to consummate the Transaction as outlined in this letter.

1.      Transaction and Purchase Price

We propose to acquire all of the outstanding Shares of the Company not beneficially owned by us at a purchase price equal to US$5.91 per Share in cash through a merger of an acquisition vehicle newly formed by the Buyer Parties with and into the Company.

2.      Financing 

We intend to finance the Transaction with a combination of equity capital and third party debt. Equity financing will be provided by the Buyer Parties, and any additional equity investor who may be admitted as a Buyer Party, in the form of cash and rollover equity in the Company. Debt Financing is expected to be provided by loans from third party financial institutions. We are confident that we can timely secure adequate financing to consummate the Transaction.

3.      Due Diligence 

We believe that we will be in a position to complete customary business, legal and financial due diligence for the Transaction in a timely manner and in parallel with discussions on definitive agreements.

4.      Definitive Agreements 

We have engaged Davis Polk & Wardwell LLP as our U.S. legal counsel.  We are prepared to negotiate and finalize definitive agreements for the Transaction promptly.  These documents will include provisions typical for transactions of this type.

5.      Confidentiality 

The Buyer Parties will, as required by law, promptly file an amendment to Schedule 13D with the Securities and Exchange Commission to disclose this letter.  We are sure you will agree that it is in all of our interests to ensure that we otherwise proceed in a strictly confidential manner, unless otherwise required by law, until we have executed definitive agreements or terminated our discussions.

6.      Process

We believe that the Transaction will provide value to the Company’s stockholders. We recognize of course that the board of directors of the Company will evaluate the proposed Transaction independently before it can make its determination whether to endorse it. In considering the Transaction, you should be aware that we are interested only in acquiring the outstanding Shares that the Buyer Parties do not already own, and that the Buyer Parties do not intend to sell their stake in the Company to a third party.

7.      No Binding Commitment 

This proposal is not a binding offer, agreement or agreement to make a binding offer or agreement at any point in the future. This letter is a preliminary indication of interest by the Buyer Parties and does not contain all matters upon which agreement must be reached in order to consummate the Transaction, nor does it create any binding rights or obligations in favor of any person. The parties will be bound only upon the execution of mutually agreeable definitive documentation.

* * * * * *

In closing, we would like to express our commitment to working together to bring this Transaction to a successful and timely conclusion. Should you have any questions regarding this proposal, please do not hesitate to contact us. We look forward to hearing from you.

Yours sincerely,

Liang Zhang
/s/ Liang Zhang

Beams Power Investment Limited

By: /s/ Xiuqing Meng
Name: Xiuqing Meng
Title: Director

(LPTH) Exhibiting at SPIE Photonics West 2016

LightPath to Show New Products to an Expected 20,000 Attendees and 1,250 Vendors

(TUES) Announces Reporting Date for Q2 Fiscal 2016 Financial Results

DALLAS, Jan. 14, 2016  — Tuesday Morning Corporation (NASDAQ:TUES) today announced that the Company will hold a conference call to discuss its second quarter fiscal 2016 financial results on Friday, January 29^th, 2016 at 8:00 am Central Time. A press release detailing the Company’s financial results will be issued before the market opens and prior to the conference call.

A live webcast of the conference call will be available in the investor relations section of the Company’s website, www.tuesdaymorning.com. Investors and analysts interested in participating in the call are invited to dial (877) 312-5376 approximately ten minutes prior to the start of the call. A replay of the webcast will be posted on the website for 90 days. A replay of the conference call will also be available from 11:00 am Central Time Friday, 1/29/2016 through 10:59 pm Central Time, Sunday, 1/31/2016 by dialing (855) 859-2056 or (404) 537-3406 and entering conference ID number 28918021.

About Tuesday Morning

Tuesday Morning Corporation (NASDAQ:TUES) is a leading off-price retailer specializing in selling deeply discounted, upscale decorative home accessories, housewares, seasonal goods and famous-maker gifts.  The Company is nationally known for providing a fresh selection of brand name, high-quality merchandise – never seconds or irregulars – at prices well below those of department and specialty stores, catalogues and online retailers.  Based in Dallas, Texas, the Company opened its first store in 1974 and currently operates over 750 stores in 41 states.  More information and a list of store locations may be found on our website at www.tuesdaymorning.com.

CONTACT: Farah Soi/Caitlin Morahan
ICR                                    
203-682-8200
Farah.Soi@icrinc.com
Caitlin.Morahan@icrinc.com

MEDIA: Jonathan Morgan/Jennifer Sanders
PERRY STREET COMMUNICATIONS
214-965-9955

(IPCI) Announces Successful Bioequivalence Results, Rexista™ Oxycodone XR

TORONTO, Jan. 14, 2016  — Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that pivotal bioequivalence trials of the Company’s Rexista™ Oxycodone XR (abuse deterrent oxycodone hydrochloride) extended release tablets, dosed under fasted and fed conditions, had demonstrated bioequivalence to Oxycontin® (oxycodone hydrochloride) extended release tablets as manufactured and sold in the United States by Purdue Pharma LP. The study design was based on United States Food and Drug Administration (“FDA”) recommendations and compared the lowest and highest strengths of exhibit batches of the Company’s Rexista™ Oxycodone XR to the same strengths of Oxycontin®. The results show that the ratios of the pharmacokinetic metrics, C_max, AUC_0-t and AUC_0-f  for Rexista™ vs. Oxycontin®, are within the interval of 80% – 125% required by the FDA with a confidence level exceeding 90%.

The Company had earlier announced, in March 2015, that topline data results of three definitive Phase I pharmacokinetic clinical trials (single dose fasting, single dose steady-state fasting, and single dose fed), conducted on pilot batches of the Company’s Rexista™ Oxycodone XR, all met the FDA bioequivalence criteria when compared to the existing branded drug Oxycontin®.

The Company had also earlier announced, in May 2015, that the FDA had provided the Company with notification regarding its Investigational New Drug Application (“IND”) submission for Rexista™ Oxycodone XR.  The notification from the FDA had stated that the Company would not be required to conduct Phase III studies if bioequivalence to Oxycontin® was demonstrated.

Having now demonstrated such bioequivalence for its Rexista™ Oxycodone XR product to be marketed upon FDA approval, the Company intends to complete the regulatory filing requirements and file a New Drug Application (“NDA”) for Rexista™ Oxycodone XR with the FDA within the next 6 months in accordance with the NDA 505(b)(2) regulatory pathway.  There can be no assurance that the FDA will ultimately approve the NDA for the sale of Rexista™ Oxycodone XR in the U.S. market, or that it will ever be successfully commercialized.

“We take great pride in being the first pharmaceutical company, to the best of our knowledge, to have demonstrated bioequivalence in both fasted and fed conditions to the brand reference drug Oxycontin®.  This enables us to accelerate the development and commercialization of our abuse deterrent Rexista™ Oxycodone XR product candidate without the need for costly and time-consuming Phase III efficacy trials,” stated Dr. Isa Odidi, CEO and co-founder of Intellipharmaceutics. “We look forward to filing an NDA within the next six months, which we hope will lead to a positive contribution in addressing an unmet need in opioid abuse and addiction.”

Rexista™ Oxycodone XR

Rexista™ Oxycodone XR is the Company’s non-generic extended release formulation intended for the management of moderate to severe pain when an around-the-clock analgesic is required. The formulation is intended to present a significant barrier to tampering when subjected to various forms of anticipated physical and chemical manipulation commonly used by abusers. It is also designed to prevent dose dumping when inadvertently or intentionally co-administered with alcohol. In addition, when crushed or pulverized and hydrated, the proposed extended release formulation is designed to coagulate instantaneously and entrap the drug in a viscous hydrogel, which is intended to prevent syringing, injecting or snorting.

About Intellipharmaceutics

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company’s patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of products (our dexmethylphenidate hydrochloride extended-release capsules for the 15 and 30 mg strengths which received final FDA approval) and product candidates in various stages of development, including Abbreviated New Drug Applications (“ANDAs “) filed with the FDA (and one Abbreviated New Drug Submission (“ANDS”)  filed with Health Canada) in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.

Intellipharmaceutics also has NDA 505(b)(2) specialty drug product candidates in its development pipeline. These include Rexista™ Oxycodone XR, an abuse deterrent oxycodone based on its proprietary nPODDDS™ novel Point Of Divergence Drug Delivery System and PODRAS™ Paradoxical OverDose Resistance Activating System, and Regabatin™ XR pregabalin extended-release capsules. Our current development effort is increasingly directed towards improved difficult-to-develop controlled-release drugs which follow an NDA 505(b)(2) regulatory pathway. The Company has increased its research and development emphasis towards new product development, facilitated by the 505(b)(2) regulatory pathway, by advancing the product development program for both Rexista™ and Regabatin™.  The 505(b)(2) pathway (which relies in part upon the approving agency’s findings for a previously approved drug) both accelerates development timelines and reduces costs in comparison to NDAs for new chemical entities. An advantage of our strategy for development of NDA 505(b)(2) drugs is that our product candidates can, if approved for sale by the FDA, potentially enjoy an exclusivity period which may provide for greater commercial opportunity relative to the generic ANDA route.

Certain statements in this document constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or “forward-looking information” under the Securities Act (Ontario). These statements include, without limitation, statements expressed or implied regarding our plans, goals and milestones, status of developments or expenditures relating to our business, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future sales, revenues and profitability, projected costs, and market penetration. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “plans to,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” “intends,” “could,” or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of our forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of known and unknown risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those stated in or implied by the forward-looking statements. Risks, uncertainties and other factors that could affect our actual results include, but are not limited to, the effects of general economic conditions, securing and maintaining corporate alliances, our estimates regarding our capital requirements, and the effect of capital market conditions and other factors, including the current status of our product development programs, on capital availability, the potential dilutive effects of any future financing and the expected use of any proceeds from any offering of our securities, our ability to maintain compliance with the continued listing requirements of the principal markets on which our securities are traded, our programs regarding research, development and commercialization of our product candidates, the timing of such programs, the timing, costs and uncertainties regarding obtaining regulatory approvals to market our product candidates and the difficulty of predicting the timing and results of any product launches, and the timing and amount of any available investment tax credits, the actual or perceived benefits to users of our drug delivery technologies, products and product candidates as compared to others, our ability to establish and maintain valid and enforceable intellectual property rights in our drug delivery technologies, products and product candidates, the scope of protection provided by intellectual property for our drug delivery technologies, products and product candidates, the actual size of the potential markets for any of our products and product candidates compared to our market estimates, our selection and licensing of products and product candidates, our ability to attract distributors and collaborators with the ability to fund patent litigation and with acceptable development, regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts, sources of revenues and anticipated revenues, including contributions from distributors and collaborators, product sales, license agreements and other collaborative efforts for the development and commercialization of product candidates, our ability to create an effective direct sales and marketing infrastructure for products we elect to market and sell directly, the rate and degree of market acceptance of our products, delays that may be caused by changing regulatory requirements, the difficulty in predicting the timing of regulatory approval and the timing of launch of competitive products, the difficulty of predicting the impact of competitive products on volume and pricing, the inability to forecast wholesaler demand and/or wholesaler buying patterns, the seasonal fluctuation in the numbers of prescriptions written for our dexmethylphenidate hydrochloride extended-release capsules which may produce substantial fluctuations in revenues, the timing and amount of insurance reimbursement for our products, changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products, the success and pricing of other competing therapies that may become available, our ability to retain and hire qualified employees, the availability and pricing of third party sourced products and materials, difficulties or delays in manufacturing, the manufacturing capacity of third-party manufacturers that we may use for our products, the successful compliance with FDA, Health Canada and other governmental regulations applicable to the Company and its third party manufacturers’ facilities, products and/or businesses, difficulties, delays or changes in the FDA approval process or test criteria for ANDAs and NDAs and risks associated with cyber-security and vulnerability of the Company’s digital information and the digital information of the Company’s commercialization partner(s). Additional risks and uncertainties relating to the Company and our business can be found in the “Risk Factors” section of our latest annual information form, our latest Form 20-F, and our latest Form F-3 (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada and the U.S., which are available on www.sedar.com and www.sec.gov. The forward-looking statements reflect our current views with respect to future events and are based on what we believe are reasonable assumptions as of the date of this document, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Company Contact:

Intellipharmaceutics International Inc.
Domenic Della Penna
Chief Financial Officer
416-798-3001 ext 106
investors@intellipharmaceutics.com

Investor Contact:

ProActive Capital
Kirin Smith
646-863-6519
ksmith@proactivecapital.com

(AMS) Announces Permanent Financing Package

AMERICAN SHARED HOSPITAL SERVICES (NYSE MKT:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has entered into a definitive agreement for the permanent financing, subject to regulatory approval and standard conditions precedent, of its proton therapy center now under construction at UF (University of Florida) Health Cancer Center – Orlando Health in Florida. This center, which will employ the MEVION S250 proton therapy system, is expected to begin treating patients in April of this year.

Chairman and Chief Executive Officer Ernest A. Bates, M.D., said, “This financing agreement is an important milestone in the development of AMS’ proton business, a business we believe represents an extraordinary growth opportunity for our company. We have guided this initial project from its inception through delivery and installation of the MEVION S250 system, obtained permanent financing, and look forward to Orlando Health initiating patient treatments soon. This demonstrates that we have the resources and know-how to get these complex projects done, an important consideration for other hospitals around the country that have expressed interest in partnering with AMS to develop proton centers of their own. We believe that the clinical advantages of proton therapy in the treatment of a wide range of cancers will support rapid growth in the application of this advanced therapeutic technology, and we are convinced that AMS will be a significant beneficiary.”

About AMS

American Shared Hospital Services provides turnkey technology solutions for advanced radiosurgical and radiation therapy services. AMS is the world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations and trigeminal neuralgia (facial pain). The Company also offers the latest IGRT and IMRT systems, as well as its proprietary Operating Room for the 21st Century^SM concept. AMS owns a common stock investment in Mevion Medical Systems, Inc., developer of the compact MEVION S250 Proton Therapy System.

About Orlando Health

Orlando Health is a $2.3 billion not-for-profit health care organization and a community-based network of physician practices, hospitals, and outpatient care centers throughout Central Florida. The organization includes Orlando Health Physician Group and Physician Associates, two of the largest multi-specialty practices in Central Florida, ownership in an outpatient surgery center, and eight wholly-owned or affiliated hospitals. An Orlando Health subsidiary holds a 51 percent interest in an entity operating five outpatient imaging centers.

Orlando Health is home to the area’s only Level One Trauma Centers for adults and pediatrics and is a statutory teaching hospital system that offers both specialty and community hospitals. They are: Orlando Regional Medical Center; Dr. P. Phillips Hospital; South Seminole Hospital; Health Central Hospital, the Arnold Palmer Medical Center, which consists of Arnold Palmer Hospital for Children and Winnie Palmer Hospital for Women & Babies; the UF Health Cancer Center – Orlando Health, South Lake Hospital (50 percent affiliation); and St. Cloud Regional Medical Center (20 percent affiliation). Areas of clinical excellence are heart and vascular, cancer care, neurosciences, surgery, pediatric orthopedics and sports medicine, neonatology, and women’s health.

More than 2,000 physicians have privileges at Orlando Health, which is also one of the area’s largest employers with more than 15,000 employees who support our philosophy of providing high quality care and service that revolves around patients’ needs. We prove this everyday with over 100,000 inpatient admissions and nearly 900,000 outpatient visits each year. In all, Orlando Health serves 1.8 million Central Florida residents and more than 4,500 international patients annually. Additionally, Orlando Health provides nearly $235 million in support of community health needs. More information can be found at http://www.orlandohealth.com.

Safe Harbor Statement

This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services, which involve risks and uncertainties including, but not limited to, the risks of the Gamma Knife and radiation therapy businesses, the risks of developing The Operating Room for the 21st Century program, the risks of investing in a development-stage company, Mevion Medical Systems, Inc., and the risks of the timing, financing, and operations of the Company’s proton therapy business. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, its quarterly reports on Form 10-Q for the three months ended March 31, 2015, June 30, 2015, and September 30, 2015, and the definitive Proxy Statement for the Annual Meeting of Shareholders held on June 16, 2015.

(COYN) Hosts Law Enforcement Officials and Community Leaders at NY-NJ Launch Event

DALLAS, Jan. 14, 2016  — COPsync, Inc. (NASDAQ:COYN), which operates the nation’s largest law enforcement in-car information sharing and communication network, and the COPsync911 threat-alert service for schools, government buildings, hospitals and other potentially at-risk facilities, hosted a meeting January 7, 2016 in New York City to announce plans to launch COPsync’s safety and security solutions for schools, law enforcement agencies and municipalities across the states of New York and New Jersey.

COPsync Chief Executive Officer Ronald A. Woessner showcased the lifesaving COPsync Network and COPsync911 technology to a select audience of C-level executives, law enforcement and education officials, and political leaders, including representatives from the New York State Troopers Police Benevolent Association, the New York judiciary, and U.N. Ambassador Jack Brewer.

Mr. Woessner described how the COPsync Network provides what is missing in today’s law enforcement – having the ability to communicate in real-time about crimes in progress and share mission-critical information across agency jurisdictional boundaries, all for the purpose of keeping law enforcement officers safer and enabling them to interdict crime and criminal behavior more effectively. He also highlighted how COPsync’s companion product, COPsync911, fulfills communities’ demands for safer schools by informing the closest officers of a school threat faster and equipped with up-to-the-minute situational information unfolding at the scene.

Describing the event, Ambassador Jack Brewer stated, “The meeting was an instrumental step in the COPsync expansion efforts in the Northeast, and it will be exciting to see COPsync expand across the length and breadth of the United States. The COPsync Network protects police officers and gives them the tools to do their jobs more effectively, while COPsync911 protects at-risk facilities, schools and schoolchildren, and provides a measure of liability protection for school administrators and school boards because they have taken steps to provide the safest environment for the students and staff.”

“We are honored to have met with political leaders and law enforcement officials who share our vision and recognize the capabilities of the COPsync Network in protecting law enforcement officers, children and communities,” commented Mr. Woessner. “We look forward to continuing to work with all involved parties to further expand the Company’s customer footprint in municipalities, schools and law enforcement agencies across the great states of New York and New Jersey and throughout the country.”

COPsync’s solutions are being supported and endorsed by a growing number of strategic alliances throughout the nation, which include The Blue Alert Foundation, developer of the Blue Alert system, which provides law enforcement officers a means to become aware of threats made against them. The Company also is actively expanding its footprint in various targeted territories with the garnered support of several celebrity endorsers, brand ambassadors and community leaders as well as through ongoing launch events and awareness campaigns to be announced soon.

About COPsync, Inc.

COPsync, Inc. (COYN) is a technology company that improves communication between and among law enforcement officers and agencies from differing jurisdictions to help them prevent and respond more quickly to crime. The COPsync Network connects law enforcement officers and agencies to a common communications system, which gives officers instant access to actionable, mission-critical data and enables them to share information and communicate in real-time with other officers and agencies, even those hundreds and thousands of miles away. The Network’s companion COPsync911 threat-alert system, enables schools, courts, hospitals, government buildings, energy, telecommunications and other potentially at-risk facilities to automatically and silently send threat alerts directly to local law enforcement officers in their patrol cars in the event of a crisis, thereby speeding first responder response times and saving minutes when seconds count. The COPsync Network saves officer and citizen lives, reduces unsolved crimes and assists in apprehending criminals and interdicting criminal behavior — through such features as a nationwide officer safety alert system, GPS/auto vehicle location and distance-based alerts for crimes in progress, such as school crisis situations, child abductions, bank robberies and police pursuits. The COPsync Network also eliminates manual processes and increases officer productivity by enabling officers to write electronic tickets, accident reports, DUI forms, arrest forms and incident and offense reports. The company also sells VidTac®, an in-vehicle, software-driven video system for law enforcement. Visit www.copsync.com and www.copsync911.com for more information.

Contact:
For COPsync:
Ronald A. Woessner
Chief Executive Officer
972-865-6192
invest@copsync.com

Media:
Fred Sommer
Senior Consultant
Investor Relations
Ascendant Partners, LLC.
732-410-9810
fred@ascendantpartnersllc.com

(LEI) Schedules Conference Call To Discuss Planned Mid-Continent Acquisition

HOUSTON, Jan. 14, 2016  — Lucas Energy, Inc. (NYSE MKT: LEI) (“Lucas” or the “Company”) announced today that is has scheduled a conference call to discuss the recent announcement of the proposed acquisition of oil and natural gas properties in the Hunton play in the Mid-Continent region in addition to the new strategic direction and rebranding of the Company.  The conference call is scheduled for 11:00 a.m. Eastern Time (10:00 a.m. Central Time) on Thursday, January 21, 2016.  There will be an accompanying slide presentation posted on the Company’s website just prior to the call.  Investors may participate by phone or via audio webcast.

About Lucas Energy, Inc.

Lucas Energy (NYSE MKT: LEI) is engaged in the development of crude oil and natural gas in the Austin Chalk and Eagle Ford formations in South Texas. Based in Houston, Lucas’s management team is committed to building a platform for growth and the development of its five million barrels of proved Eagle Ford and other oil reserves while continuing its focus on operating efficiencies and cost control.

Forward Looking Statements

In addition to historical information contained herein, this news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, subject to various risks and uncertainties that could cause the Company’s actual results to differ materially from those in the “forward-looking” statements. Although Lucas believes that the expectations reflected in such forward-looking statements are reasonable, these statements involve risks and uncertainties that may cause actual future activities and results to be materially different from those suggested or described in this news release. These risks and uncertainties include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the asset purchase agreement; and the inability to complete the transaction due to the failure to satisfy any of the conditions to completion of the transaction. These also include risks inherent in natural gas and oil drilling and production activities, including risks of fire, explosion, blowouts, pipe failure, casing collapse, unusual or unexpected formation pressures, environmental hazards, and other operating and production risks, which may temporarily or permanently reduce production or cause initial production or test results to not be indicative of future well performance or delay the timing of sales or completion of drilling operations; delays in receipt of drilling permits; risks with respect to natural gas and oil prices, a material decline which could cause Lucas to delay or suspend planned drilling operations or reduce production levels; risks relating to the availability of capital to fund drilling operations that can be adversely affected by adverse drilling results, production declines and declines in natural gas and oil prices; risks relating to unexpected adverse developments in the status of properties; risks relating to the absence or delay in receipt of government approvals or fourth party consents; and other risks described in Lucas’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the SEC, available at the SEC’s website at www.sec.gov. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The Company takes no obligation to update or correct its own forward-looking statements, except as required by law, or those prepared by third parties that are not paid for by the Company. The Company’s SEC filings are available at http://www.sec.gov.

Important Information

In connection with the planned acquisition described above, Lucas currently intends to file a registration statement and a proxy statement with the Securities and Exchange Commission (the “SEC”). This communication is not a substitute for any proxy statement, registration statement, proxy statement/prospectus or other document Lucas may file with the SEC in connection with the proposed transaction. Prospective investors are urged to read the registration statement and the proxy statement, when filed as they will contain important information. Any definitive proxy statement(s) (if and when available) will be mailed to stockholders of Lucas. Prospective investors may obtain free copies of the registration statement and the proxy statement, when filed, as well as other filings containing information about Lucas, without charge, at the SEC’s website (www.sec.gov). Copies of Lucas’s SEC filings may also be obtained from Lucas without charge at Lucas’ website (www.lucasenergy.com) or by directing a request to Lucas at (713) 528-1881. This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

INVESTORS SHOULD READ THE PROXY STATEMENT AND OTHER DOCUMENTS TO BE FILED WITH THE SEC CAREFULLY BEFORE MAKING A DECISION CONCERNING THE TRANSACTION.

Participants in Solicitation

Lucas and its directors and executive officers and other members of management and employees are potential participants in the solicitation of proxies in respect of the proposed transaction. Information regarding Lucas’s directors and executive officers is available in Lucas’s Annual Report on Form 10-K for the year ended March 31, 2015, filed with the SEC on July 14, 2015 and Lucas’s definitive proxy statement on Schedule 14A, filed with the SEC on February 9, 2015. Additional information regarding the interests of such potential participants will be included in the registration statement and proxy statement to be filed with the SEC by Lucas in connection with the proposed transaction and in other relevant documents filed by Lucas with the SEC. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC when they become available.

Contact:
Carol Coale / Ken Dennard
Dennard Lascar Associates, LLC
(713) 529-6600
ccoale@dennardlascar.com
ken@dennardlascar.com
http://www.dennardlascar.com

(LAYN) Layne Christensen Appoints Alan P. Krusi to its Board of Directors

THE WOODLANDS, Texas, Jan. 13, 2016  — Layne Christensen (NASDAQ: LAYN) (“Layne”) today announced that Mr. Alan P. Krusi has been appointed to its Board of Directors, effective January 15, 2016.

Mr. Krusi was President of Strategic Development at AECOM Technology Corporation, a global provider of professional technical and management support services, from 2008 until 2015. As head of Strategic Development, he headed the firm’s mergers and acquisitions program and was a member of the AECOM Executive Management Team. He also oversaw strategic planning and enterprise risk management at various times.  From 2003 to 2008, Mr. Krusi was President and Chief Executive Officer of Earth Tech, Inc., a subsidiary of Tyco International, a global provider of consulting, engineering, construction and operational services of water treatment facilities. He was responsible for the company’s overall growth strategy and operational performance, including investments in the firm’s developed, owned, and operated water treatment plants.

Prior to joining Earth Tech, Inc., Mr. Krusi was President of the Construction Services Division of URS Corporation, which included both the largest U.S. construction management firm and one of the top U.S. environmental remediation contractors.  Mr. Krusi joined URS in 1999 through the merger with Dames & Moore Group where he spent over 15 years as a senior manager. Mr. Krusi currently serves on the Board of publicly-traded Comfort Systems USA, Alacer Gold Corporation and Blue Earth, Inc.

Michael J. Caliel, Layne’s President and CEO, commented, “We are delighted that Alan Krusi has agreed to join the Layne Board of Directors. Alan brings to our Board nearly four decades of executive leadership and corporate development experience in our core industries, including global water management, which aligns itself extremely well with our water focused strategy. With his many accomplishments and his extensive strategic, financial and corporate governance expertise, the Board of Directors and the management team look forward to his contributions to the organization.”

About Layne

Layne is a global solutions provider to the world of essential natural resources—water, minerals and energy. We offer innovative, sustainable products and services with an enduring commitment to safety, excellence and integrity.

Contacts

J. Michael Anderson
Chief Financial Officer
281-475-2694
michael.anderson@layne.com

Dennard Lascar Associates
Jack Lascar
713-529-6600
jlascar@dennardlascar.com

(RRM) Fashion One Television Upgrades Media Services Contract With RR Media

Managing and Delivering Broadcast Channels With Service Upgrade to Include Linear Streaming to Online Platforms

(UBIC) Brings in Top Executive Talent in North America

Joining the UBIC Executive team are David Ahrens, Chief Marketing Officer and Margaret Shaw Lilani as Senior Vice President, Review and Professional Services

SAN FRANCISCO, Jan. 13, 2016  — UBIC, Inc. (Nasdaq:UBIC) (TSE:2158), a leading provider of international litigation support and big-data analysis services, announced today that it has hired two key executives to help the company expand its operations in North America and also globally. Joining the UBIC executive team are David Ahrens in the role of Chief Marketing Officer, and Margaret Shaw Lilani as Senior Vice President, Review and Professional Services.

Photos accompanying this announcement are available at

As Chief Marketing Officer, Mr. Ahrens will be responsible for developing an integrated marketing and communications plan for the unified UBIC entity formed by the acquisition of Evolve and TechLaw, and rolling in UBIC North America into a centralized marketing function. This will include elements of lead generation, public relations, event management, a customer reference program, product and solution marketing, as well as digital marketing efforts. His vast experience in the software industry across marketing, business development and corporate strategy will provide valuable structure and processes to support the high growth objectives of the business. Previously, Mr. Ahrens was the CMO of Marsh ClearSight, and prior to that held senior management roles at both SAP and SAS.

Ms. Lilani joins as the Senior Vice President, Review and Professional Services and will be responsible for UBIC’s Review & Professional Services business globally. Ms. Lilani will focus on the integration of post-acquisition global service delivery and enhanced client experience through the application of advanced review workflows and best-of-breed technology. She will support international clients and law firms on cross border matters ensuring access to Tier 1 review facilities, people and technology and providing comprehensive solutions to the complex legal problems of UBIC’s clients. Additionally, she will work closely with UBIC’s Sales organization. Ms. Lilani is a trained attorney and has held previous executive roles at Epiq Systems and Kelly Services.

“As we continue our aggressive growth trajectory in the eDiscovery market, we enter 2016 unified, focused and ready to set the bar higher on client satisfaction”, says Andy F. Jimenez, Chief Executive Officer at UBIC North America. “We have great people here at UBIC today. And with David Ahrens joining our executive team, we have a proven leader who can bring our marketing and communications to another level in an articulate and resounding fashion. Margaret Lilani is an industry veteran who will deepen our leadership team, providing a clear path for clients to technology-enabled services that are faster and better than any in the industry.”

About UBIC, Inc.

UBIC, Inc. (Nasdaq:UBIC) (TSE:2158) supports the analysis of big data based on behavior informatics by utilizing its technology, “KIBIT”. UBIC’s KIBIT technology is driven by UBIC AI based on knowledge acquired through its litigation support services. The KIBIT incorporates experts’ tacit knowledge, including their experiences and intuitions, and utilizes that knowledge for big data analysis. UBIC continues to expand its business operations by applying KIBIT to new fields such as healthcare and marketing.

UBIC was founded in 2003 as a provider of e-discovery and international litigation support services. These services include the preservation, investigation and analysis of evidence materials contained in electronic data, and computer forensic investigation. UBIC provides e-discovery and litigation support by making full use of its data analysis platform, “Lit i View®”, and its Predictive Coding technology adapted to Asian languages.

For more information about UBIC, contact usinfo@ubicna.com or visit http://www.ubic-global.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the amount of data that UBIC expects to manage this year and the potential uses for UBIC’s new service in intellectual property-related litigation, contain forward-looking statements. UBIC may also make written or oral forward-looking statements in its reports filed with, or furnished to, the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about UBIC’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: UBIC’s goals and strategies; UBIC’s expansion plans; the expected growth of the data center services market; expectations regarding demand for, and market acceptance of, UBIC’s services; UBIC’s expectations regarding keeping and strengthening its relationships with customers; UBIC’s plans to invest in research and development to enhance its solution and service offerings; and general economic and business conditions in the regions where UBIC provides solutions and services. Further information regarding these and other risks is included in UBIC’s reports filed with, or furnished to the Securities and Exchange Commission. UBIC does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of this press release, and UBIC undertakes no duty to update such information, except as required under applicable law.

CONTACT: 
UBIC Global PR
UBIC North America, Inc.
Tel: (212) 924-8242
global_pr@ubic.co.jp

(MCHP) Announces (ATML) Acquisition Proposal Deemed A “Superior Proposal” By BOD

CHANDLER, Ariz., Jan. 13, 2016  — Microchip Technology Incorporated (NASDAQ: MCHP), a leading provider of microcontroller, mixed-signal, analog and Flash-IP solutions today announced that it was informed last night that the Board of Directors of Atmel Corporation (NASDAQ: ATML) had determined that Microchip’s  proposal to acquire Atmel for $8.15 per share in a cash and stock transaction constitutes a “Superior Proposal” under the terms of Atmel’s merger agreement with Dialog Semiconductor PLC.

Under the terms of Microchip’s proposal, stockholders of Atmel will receive $7.00 per share in cash and $1.15 per share in Microchip common stock, valued at the average closing sale price for a share of Microchip common stock for the ten most recent trading days ending on the last trading day prior to the closing. The maximum number of Microchip shares to be issued in the transaction is 13.0 million, after which the cash consideration per share will be increased such that the combined cash and stock consideration will remain at $8.15 per share. Microchip was informed that Atmel has given written notice to Dialog of its intent to change its recommendation and terminate the Dialog transaction in favor of the Microchip proposal. As a result, Atmel will be entitled to terminate the Dialog merger agreement if Dialog does not make, within four business days following the receipt of the notice, a written, binding proposal that would cause the Microchip proposal to no longer constitute a “Superior Proposal.”

“The combined business of Microchip and Atmel will create a microcontroller, analog and internet of things (IoT) powerhouse. Atmel’s portfolio of microcontrollers, wireless, touch, memory and automotive products complements and enhances many of Microchip’s solutions in these areas.  We believe that combining Atmel’s business with Microchip’s business will offer our combined customers a broader range of innovative solutions to serve their needs, while creating significant long-term stockholder value,” said Steve Sanghi, President and CEO of Microchip.

“Microchip’s enduring vision is to be the very best embedded control solutions company ever. Our strategy behind this vision is to enable the growing market for smart, connected and secure solutions for the automotive, industrial, office automation, consumer and telecom markets. We believe that the combined microcontroller, analog, memory, automotive, security, computing, networking, wireless, touch, timing and technology licensing product lines of Microchip and Atmel will present a powerful portfolio of innovative solutions for these growing markets.  We also believe this acquisition will further enhance our analog and mixed-signal opportunities as we expect to attach these products to an expanded set of microcontroller customer applications,” said Ganesh Moorthy, COO of Microchip.

If Microchip and Atmel execute a merger agreement on the terms proposed by Microchip, the transaction is expected to be immediately accretive to Microchip’s non-GAAP earnings per share following the closing of such transaction.

J.P. Morgan is acting as Microchip’s exclusive financial advisor. Wilson Sonsini Goodrich & Rosati, P.C. is acting as Microchip’s legal advisor.

There will be no conference call held in connection with this press release.

About Microchip Technology

Microchip Technology Inc. (NASDAQ:  MCHP) is a leading provider of microcontroller, mixed-signal, analog and Flash-IP solutions, providing low-risk product development, lower total system cost and faster time to market for thousands of diverse customer applications worldwide.  Headquartered in Chandler, Arizona, Microchip offers outstanding technical support along with dependable delivery and quality.  For more information, visit the Microchip website at http://www.microchip.com.

Forward Looking Statements

The statements in this release relating to the combined business of Microchip and Atmel creating a microcontroller, analog and IoT powerhouse,  that Atmel’s portfolio of microcontrollers, wireless, touch, memory and automotive products complements and enhances many of Microchip’s solutions in these areas, our belief that combining Atmel’s business with Microchip’s business will offer our combined customers a broader range of innovative solutions to serve their needs, while creating significant long-term stockholder value, Microchip’s vision to be the very best embedded control solutions company ever, Microchip’s strategy to enable the growing market for smart, connected and secure solutions for the automotive, industrial, office automation, consumer and telecom markets, our belief that the combined microcontroller, analog, memory, automotive, security, computing, networking, wireless, touch, timing and technology licensing product lines of Microchip and Atmel will present a powerful portfolio of innovative solutions for these growing markets, our belief that this acquisition will further enhance our analog and mixed-signal opportunities as we expect to attach these products to an expanded set of microcontroller customer applications, and that the transaction is expected to be immediately accretive to Microchip’s non-GAAP earnings per share are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to a number of business, economic, legal and other risks that are inherently uncertain and difficult to predict, including, but not limited to: whether Microchip and Atmel actually enter into a merger agreement and the definitive terms of such agreement, the actual timing of the closing of the acquisition if the proposed merger agreement is executed,  the satisfaction of the conditions to closing in the proposed merger agreement (including obtaining Atmel stockholder approval and regulatory clearances), any termination of the existing merger agreement between Atmel and Dialog Semiconductor or the proposed merger agreement between Microchip and Atmel, changes in demand or market acceptance of the products of Atmel or Microchip and the products of their respective customers; competitive developments; the costs and outcome of any current or future litigation involving Microchip, Atmel or the acquisition transaction; the effect of the acquisition on Microchip’s and Atmel’s existing relationships with customers and vendors and their operating results and businesses; the progress and costs of development of Microchip and Atmel products and the timing and market acceptance of  those new products; Microchip’s ability to successfully integrate Atmel’s operations and employees, retain key employees and otherwise realize the expected synergies and benefits of the transaction; fluctuations in Microchip’s stock price which would impact the number of shares that Microchip issues in the transaction; and general economic, industry or political conditions in the United States or internationally.  For a detailed discussion of these and other risk factors, please refer to the SEC filings of Microchip and Atmel including those on Forms 10-K, 10-Q and 8-K.  You can obtain copies of Forms 10-K, 10-Q and 8-K and other relevant documents for free at Microchip’s website (www.microchip.com), at Atmel’s website (www.atmel.com) (as applicable) or the SEC’s website (www.sec.gov) or from commercial document retrieval services.

Stockholders of Microchip are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date such statements are made.  Microchip undertakes no obligation to publicly update any forward-looking statements to reflect events, circumstances or new information after this January 13, 2016 press release, or to reflect the occurrence of unanticipated events.

Additional Information and Where to Find It

If Microchip and Atmel execute a merger agreement on the proposed terms, Microchip will file a Registration Statement on Form S-4 that will include a proxy statement of Atmel in connection with the acquisition transaction.  Investors and security holders are urged to read this document when it becomes available because it will contain important information about the transaction. Investors and security holders may obtain free copies of these documents (when they are available) and other documents filed with the SEC at the SEC’s web site at www.sec.gov.  Microchip, Atmel and their directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Atmel in connection with the acquisition transaction.  Information regarding the special interests of these directors and executive officers in the transaction will be included in the proxy statement/prospectus described above.  Additional information regarding the directors and executive officers of Microchip is also included in Microchip’s proxy statement for its 2015 Annual Meeting of Stockholders, which was filed with the SEC on July10, 2015.  Additional information regarding the directors and executive officers of Atmel is also included in Atmel’s proxy statement for its 2015 Annual Meeting of Stockholders, which was filed with the SEC on April 3, 2015.  These documents are available free of charge at the SEC’s web site at www.sec.gov and as described above.

Note: The Microchip name and logo are registered trademarks of Microchip Technology Inc. in the USA and other countries.  All other trademarks mentioned herein are the property of their respective companies.

INVESTOR RELATIONS CONTACT:
J. Eric Bjornholt – CFO  (480) 792-7804

(WILN) Subsidiary Enters Into License Agreement With FEI

For media and investor inquiries, please contact:
Dave Mason
Investor Relations
LodeRock Advisors Inc.
613.688.1693
dave.mason@loderockadvisors.com

(CPAH) Achieves Cisco Compatibility Certification With the Cisco Solution Partner Program

Todd Carothers
Executive Vice President of Marketing and Products
e-mail: tcarothers@counterpath.com

(VHC) Court Issues New Order in (AAPL) Lawsuit

Ruling Covers Pending Motions Before Trial

ZEPHYR COVE, Nev., Jan. 12, 2016  — VirnetX™ Holding Corporation (NYSE MKT: VHC), an Internet security software and technology company, announced today that on January 11, 2016, in the Company’s pending litigation against Apple Inc., in the United States District Court for the Eastern District of Texas, Tyler Division, the court issued a comprehensive order with rulings on all of the pending Daubert and Dispositive motions, filed by both parties and pending before the court.

“We are pleased to have these extensive issues in the case resolved by the Court,” said Kendall Larsen, VirnetX CEO and President.  “We look forward to presenting our case to a jury on January 25^th, 2016.”

VirnetX has currently-pending patent infringement lawsuit, VirnetX Inc. v. Apple, Inc. (Case 6:12-CV-00855-LED), in United States Court for the Eastern District of Texas, Tyler Division. This Civil Action includes the remanded portions of the Civil Action Case 6:10-CV-00417-LED (VirnetX vs. Cisco et. al.). The jury selection and trial in this Civil Action is scheduled to start on January 25, 2016.

About VirnetX

VirnetX Holding Corporation is an Internet security software and technology company with patented technology for secure communications including 4G LTE security. The Company’s software and technology solutions, including its secure domain name registry and Gabriel Connection Technology™, are designed to facilitate secure communications and to create a secure environment for real-time communication applications such as instant messaging, VoIP, smart phones, eReaders and video conferencing. The Company’s patent portfolio includes over 112 U.S. and international patents and over 75 pending applications. For more information, please visit www.virnetx.com

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact, including statements regarding the  strength of VirnetX’s intellectual property, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements are based on expectations, estimates and projections about the markets in which the Company operates, management’s beliefs, and certain assumptions made by management and involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements, including but not limited to (1) the outcome of any legal proceedings that have been or may be initiated by the Company or that may be initiated against the Company, including pending and future inter partes review proceedings in the Patent and Trademark Office; (2) the ability to capitalize on the Company’s patent portfolio and generate licensing fees and revenues; (3) the ability of the Company to be successful in entering into licensing relationships with its targeted customers on commercially acceptable terms; (4) potential challenges to the validity of the Company’s patents underlying its licensing opportunities; (5) the ability of the Company to achieve widespread customer adoption of the Company’s Gabriel Communication Technology™ and its secure domain name registry; (6) the level of adoption of the 3GPP Series 33 security specifications; (7) whether or not the Company’s patents or patent applications may be determined to be or become essential to any standards or specifications in the 3GPP LTE, SAE project or otherwise; (8) the extent to which specifications relating to any of the Company’s patents or patent applications may be adopted as a final standard, if at all; and (9) the possibility that Company may be adversely affected by other economic, business, and/or competitive factors.  In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” or “plans” to be uncertain and forward-looking.  The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading “Risk Factors” in Company’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2015.  Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Company’s ability to control or predict.  Except as required by law, the Company is under no duty to update any of the forward-looking statements after the date of this press release to conform to actual results.

Contact:
Investor Relations
VirnetX Holding Corporation
775.548.1785
ir@virnetx.com

VirnetX, Gabriel Collaboration Suite, Gabriel Secure Communications Platform and GABRIEL Connection Technology are trademarks of VirnetX Holding Corporation. Other company and product names may be trademarks of their respective owners.

(RCON) Signs Agreement with PetroChina’s Qinghai Oilfield

BEIJING, Jan. 12, 2016  — Recon Technology, Ltd. (NASDAQ: RCON) (“Recon” or the “Company”), a leading independent oilfield services provider operating primarily in China, announced today that Beijing BHD Petroleum Technology Co., Ltd. (“BHD”), a subsidiary of the Company, has executed an agreement (the “Agreement”) with Qinghai Oilfield, a PetroChina Co., Ltd. (“PetroChina”) subsidiary, to sell chemical agents (the “Chemicals”) to Qinghai Oilfield. The Chemicals, including Ion Modifiers and Water Quality Stabilizers, are designed and tested by BHD and are to be used for wastewater treatment at the Qinghai Oilfield. This Agreement, which is valued at RMB 3.98 million (~$0.6 million), is expected to be completed by the end of FY2016.

This Agreement follows BHD’s recent win of a major bidding contract with PetroChina that qualified BHD as a Class A Furnace Supplier to all of PetroChina’s oilfield companies and a RMB 3.2 million (~$0.5 million) contract to supply five furnaces to PetroChina’s Huabei Oilfield.

“We continue to grow our presence at PetroChina’s oilfield companies,” said Mr. Shenping Yin, Chairman and Chief Executive Officer. “Today’s announcement follows months of efforts by our BHD team and marks another breakthrough for us with PetroChina as we seek opportunities to expand our product and service offerings. The oilfield waste water treatment segment is a brand new market for Recon. Aside from the chemicals, we expect to provide more professional waste water treatment equipment to our oilfield client in the coming year, which we are in the process of developing now. We are optimistic that this consignment sale of third party chemicals has the potential to evolve into a new line of business on a recurring basis for Recon.”

About Recon Technology, Ltd.

Recon Technology, Ltd. (NASDAQ: RCON) (“Recon”) is China’s first independent oil and gas field service company to be listed on NASDAQ. Working closely with leading global partners, Recon has achieved rapid growth supplying China’s largest oil and gas exploration companies, including Sinopec and China National Petroleum Corporation, with advanced automated technologies, efficient gathering and transportation equipment and reservoir stimulation measures. The solutions Recon provides are aimed at increasing gas and petroleum extraction levels, reducing impurities, improving safety and lowering production costs. For additional information, please visit www.recon.cn.

Cautionary Statements

Statements made in this release with respect to Recon’s current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Recon. Forward-looking statements include, but are not limited to, those statements using words such as “believe,” “expect,” “plans,” “strategy,” “prospects,” “forecast,” “estimate,” “project,” “anticipate,” “aim,” “intend,” “seek,” “may,” “might,” “could” or “should,” and words of similar meaning in connection with a discussion of future operations, financial performance, events or conditions. From time to time, oral or written forward-looking statements may also be included in other materials released to the public. These statements are based on management’s assumptions, judgments and beliefs in light of the information currently available to it. Recon cautions investors that a number of important risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking statements, including but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. Therefore investors should not place undue reliance on such forward-looking statements. Actual results may differ significantly from those set forth in the forward-looking statements. 

All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact:

Recon Technology, Ltd.
Jia Liu, Chief Financial Officer
Tel: +86-10-8494-5799
Email: info@recon.cn

Weitian Investor Relations
Tina Xiao
Tel: +1-917-609-0333
Email: tina.xiao@weitian-ir.com

(SGI) Appoints Nina Richardson to Board of Directors

(MOXC) Covered by Crystal Equity Research

(FUEL) a Visionary in Gartner’s 2016 Magic Quadrant for Digital Marketing Hubs

Rocket Fuel (NASDAQ: FUEL), a leading Programmatic Marketing Platform provider, today announced that it has been positioned by Gartner, Inc. in the “Visionaries” quadrant of the “Magic Quadrant for Digital Marketing Hubs” report for the second consecutive year.¹

“The recognition by Gartner as a visionary affirms our advancements in delivering on the marketer’s vision of finding and interacting with customers at the precise moment of influence to improve performance across both owned and paid channels,” said Simon Hayhurst, Rocket Fuel senior vice president of products. “Moment Scoring is at the core of our programmatic marketing platform’s strength in activating a wealth of data across both channels, allowing our clients to deliver moment-based marketing campaigns which improve their return on ad spend and deliver new levels of insight.”

Rocket Fuel’s Programmatic Marketing Platform

The Gartner report recognized Rocket Fuel as a visionary for its Programmatic Marketing Platform, which offers superior service and support for both a Data Management Platform (DMP) and a Demand Side Platform (DSP) to help marketers and their agencies help marketers centralize and activate data from every channel, including display, mobile, video, offline CRM data, website, and email marketing. Rocket Fuel’s unique Moment Scoring™ technology, which underpins its Programmatic Marketing Platform, is designed to learn the critical predictors of what makes one marketing action more likely than another in a particular moment, and, in real time, improves campaigns accordingly.

Additional information on Rocket Fuel’s recognition as a Visionary in the Gartner Magic Quadrant for Digital Marketing Hubs can be found here: http://rocketfuel.com/rocket-fuel-named-visionary-by-gartner.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

[1]Gartner, Magic Quadrant for Digital Marketing Hubs by Andrew Frank, Jake Sorofman, Martin Kihn, Christi Eubanks, January 5, 2016

About Rocket Fuel

A leading Programmatic Marketing Platform provider, Rocket Fuel (NASDAQ: FUEL) offers brands, agencies, and platform partners managed services, as well as a SaaS-based Data Management Platform (DMP) and Demand Side Platform (DSP), to optimize performance, awareness, and lift across marketing objectives, channels and devices. By applying artificial intelligence at big data scale, Rocket Fuel’s Moment Scoring™ technology performs a real-time calculation of each ad opportunity based on a marketer’s goal to determine the likelihood a consumer will engage in a desired action. Moment Scoring goes beyond 1:1 marketing by learning to predict what marketing actions to take with a campaign at a precise moment in time, which results in a much more efficient use of marketing dollars. Rocket Fuel serves 96 of the Ad Age 100, three of the top five agency holding company trading desks, and partners with some of the world’s leading CRM platforms, marketing platforms and systems integrators. Headquartered in Redwood City, California, Rocket Fuel has more than 20 offices worldwide.

Media Contact:
Rocket Fuel
Kristin Holloway, 650-481-6178
pr@rocketfuel.com

(CETX) CEO, Saagar Govil, Makes Forbes’ 30 Under 30 List

FARMINGDALE, N.Y., Jan. 11, 2016  — Cemtrex (NASDAQ: CETX), a diversified industrial and manufacturing leader, announced today that its Chairman and CEO was recently selected by Forbes as one of its “30 Under 30.” The list represents Forbes’ selection of the brightest young entrepreneurs, breakout talents, and change agents in 20 different sectors.

Forbes initially screened over 15,000 candidates representing the best of the best, to ultimately reach their stringent selection of outstanding individuals who were recognized under the 2016 30 Under 30. According to Caroline Howard of the publication, “In the past, youth was a handicap to professional success. Getting older meant more resources, more knowledge, more money. No more. Those who grew up in the tech age have way bigger ambitions — perfectly suited to the dynamic, entrepreneurial and impatient digital world they grew up in. If you want to change the world, being under 30 is now an advantage.”

Some names on this year’s list include recognizable names: NBA champ Stephen Curry, Star Wars: The Force Awakens leading man John Boyega, plus-sized supermodel Ashley Graham, Canadian crooner Shawn Mendes and YouTube gamer CaptainSparklez (Jordan Maron). Notable 30 Under 30 Alumni from previous years include influential people like Adele and Mark Zuckerberg.

Cemtrex’s CEO, Saagar Govil, commented, “I am honored and humbled to be recognized and associated with such an elite group of successful and innovative individuals. The people on this list have accomplished a tremendous amount in their brief careers and some of the alumni from past years are global leaders in their industries now only a few years later. Cemtrex has achieved strong success the last few years, being one of the fast growing industrial companies over the last 5 years in terms of revenue. Our goal is to continue that trend upward and keep building toward greater heights.”

About Cemtrex

Cemtrex, Inc. (NASDAQ:CETX) is a world leading diversified industrial and manufacturing company that provides a wide array of solutions to meet today’s technology challenges. Cemtrex provides manufacturing services of advanced custom engineered electronics, industrial services, monitoring instruments for industrial processes and environmental compliance, and systems for controlling particulates, hazardous gases, emissions of Greenhouse gases, and other regulated pollutants used in emissions trading globally.

www.cemtrex.com

Safe Harbor Statement
This press release contains forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date.

For further information, please contact:

Investor Relations
Cemtrex, Inc.
Phone: 631-756-9116
Email

(KONA) Announces Preliminary Fourth Quarter 2015 Restaurant Sales

Same-Store Sales Increase 3.2%

SCOTTSDALE, Ariz., Jan. 11, 2016  — Kona Grill, Inc. (NASDAQ:KONA), an American grill and sushi bar, today announced preliminary restaurant sales for the quarter ended December 31, 2015. Restaurant sales increased 20.6% to $38.1 million, compared to $31.6 million for the same quarter last year. Same-store sales increased 3.2% compared to an increase of 3.1% in the fourth quarter of 2014.

For fiscal year 2015, restaurant sales increased 20.1% to $143.0 million, compared to $119.1 million for fiscal year 2014.  The increase was driven by sales associated with the opening of seven restaurants during 2015, four of which were opened in the fourth quarter, incremental sales from five restaurants opened during 2014 and same-store sales growth of 2.0%.

Berke Bakay, President and CEO of Kona Grill, commented, “We are pleased to drive 3.2% same-store sales growth during the fourth quarter, especially given recent trends in the industry. With positive same-store sales growth in 21 of the last 22 quarters, we continue to take market share with our innovative food and drink offerings and contemporary design. Our strong sales momentum, track record of execution and a robust development pipeline make us uniquely positioned as one of the fastest growing and exciting restaurant concepts in the country.”

International Development Update

The Company recently signed a non-binding letter of intent for the development of Kona Grill restaurants in Mexico.  This letter of intent is in addition to a non-binding letter of intent for development in the Middle East.

ICR Conference

The Company will be presenting at the 18^th Annual ICR Conference at the JW Marriott Orlando Grande Lakes in Orlando, FL on Tuesday, January 12, 2016.  Berke Bakay, President and CEO, and Christi Hing, CFO, are hosting the presentation, which will begin at 10:00 am Eastern Time.  Investors and interested parties may view the investor presentation by visiting the investor relations section within the Company’s website at www.konagrill.com.

About Kona Grill

Kona Grill (NASDAQ:KONA) features a global menu of contemporary American favorites, award-winning sushi, and specialty cocktails. Kona Grill owns and operates 37 restaurants, guided by a passion for quality food and personal service. Restaurants are currently located in 19 states and Puerto Rico: Arizona (Chandler, Gilbert, Phoenix, Scottsdale); Colorado (Denver); Connecticut (Stamford); Florida (Miami, Sarasota, Tampa); Georgia (Alpharetta); Idaho (Boise); Illinois (Lincolnshire, Oak Brook); Indiana (Carmel); Louisiana (Baton Rouge); Maryland (Baltimore); Michigan (Troy); Minnesota (Eden Prairie); Missouri (Kansas City); Nebraska (Omaha); New Jersey (Woodbridge); Nevada (Las Vegas(2)); Ohio (Cincinnati, Columbus); Puerto Rico (San Juan); Texas (Austin, Dallas, El Paso, Fort Worth, Friendswood, Houston, Plano, San Antonio, The Woodlands); Virginia (Arlington, Richmond). For more information, visit www.konagrill.com.

Forward-Looking Statements

The Company reminds investors these sales figures are preliminary estimates and could differ from final audited fourth quarter and full year results. Various remarks we make about future expectations, plans, and prospects for the company constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our expectations, beliefs, intentions, plans, objectives, goals, strategies, future events, or performance and underlying assumptions and other statements that are not purely historical. These statements relate to our future financial performance and growth goals for 2016 and beyond. We have attempted to identify these statements by using forward-looking terminology such as “may,” “will,” “anticipates,” “expects,” “believes,” “intends,” “should,” or comparable terms. All forward-looking statements included in this press release are based on information available to us on the date of this release and we assume no obligation to update these forward-looking statements for any reason. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the statements. Investors are referred to the full discussion of risks and uncertainties associated with forward-looking statements and the discussion of risk factors contained in the company’s filings with the Securities and Exchange Commission.

Kona Grill Investor Relations Contact:
Kona Grill, Inc.
Christi Hing, Chief Financial Officer
(480) 922-8100
investorrelations@konagrill.com

(APOL) Explores Strategic Alternatives

Apollo Education Group, Inc. (Nasdaq: APOL) announced today that the Board of Directors has made the determination to explore strategic alternatives while the Company continues to execute its ongoing business transformation. The Board is currently in discussions that could potentially lead to a change of control of the Company. The Board believes that these actions will support and accelerate Apollo’s strategic initiatives, which include the continued growth and investment in Apollo Global and the continuation of the University of Phoenix’s transformation plan to further enhance student outcomes and provide outstanding, career relevant higher education for working adults.

The Company has retained Barclays and Credit Suisse as financial advisors and Sullivan & Cromwell as legal advisor. There can be no assurance that any transaction will be pursued or completed. Given the ongoing nature of these discussions, the Company will not make any further comment at this time.

About Apollo Education Group, Inc
Apollo Education Group, Inc. is one of the world’s largest private education providers, serving students since 1973. Through its subsidiaries, Apollo Education Group offers undergraduate, graduate, professional development and other nondegree educational programs and services, online and on-campus principally to working learners. Its educational programs and services are offered throughout the United States and in Europe, Australia, Latin America, Africa and Asia, as well as online throughout the world. For more information about Apollo Education Group, Inc. and its subsidiaries, call (800) 990-APOL or visit the Company’s website at www.apollo.edu.

Forward-Looking Statements Safe Harbor
Statements about Apollo Education Group and its business in this release which are not statements of historical fact, including statements regarding Apollo Education Group’s future strategy and plans and commentary regarding future results of operations and prospects, are forward-looking statements and are subject to the Safe Harbor provisions created by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current information and expectations and involve a number of risks and uncertainties. Actual plans implemented and actual results achieved may differ materially from those set forth in or implied by such statements due to various factors, including without limitation: (i) the impact of increased competition from traditional public universities and proprietary educational institutions; (ii) the impact of the initiatives to transform University of Phoenix into a more focused, higher retaining and less complex institution, including the near-term impact on enrollment; (iii) the impact of the Company’s ongoing restructuring and cost-reduction initiatives; (iv) impacts from actions taken by our regulators that could affect University of Phoenix’s eligibility to participate in or the manner in which it participates in U.S. federal and state student financial aid programs; (v) further delay in the University’s pending recertification by the U.S. Department of Education for participation in Title IV student financial aid programs, or any limitations or qualifications imposed in connection with any recertification; (vi) the impact of the U.S. Department of Defense (“DoD”) action to place University of Phoenix on probation in relation to participation in the DoD’s Tuition Assistance Program for active duty military students; (vii) the impact of any reduction in financial aid available to students, including active and retired military personnel, due to the U.S. government deficit reduction proposals, debt ceiling limitations, budget sequestration or otherwise; (viii) changes in University of Phoenix enrollment or student mix; and (ix) unexpected expenses or other challenges in integrating acquired businesses, consumer or regulatory impact arising from consummation of such acquisitions, and unexpected changes or developments in the acquired businesses. For a discussion of the various factors that may cause actual plans implemented and actual results achieved to differ materially from those set forth in the forward-looking statements, please refer to the risk factors and other disclosures contained in Apollo Education Group’s Form 10-K for fiscal year 2015, most recently filed 10-Q, and other filings with the Securities and Exchange Commission which are available at www.apollo.edu.

Brunswick Group
Tripp Kyle / Tom Maginnis
(212) 333 3810
apollo@brunswickgroup.com

(ANY) Collab. w/ (MSFT) to Bring SnapCLOUD Adopters to Azure Marketplace

Simple and expandable storage platform to provision enterprise cloud storage proves a winning combination in Microsoft Marketplace

San Jose, California–(January 11, 2016) – Sphere 3D Corp. (NASDAQ: ANY), a containerization, virtualization and data management solutions provider and parent company of Overland Storage and Tandberg Data, today announced encouraging initial results from its Microsoft Azure joint marketing campaign. In-market tactics launched in late November 2015 were directed to a control portion, subset of its dedicated customers that use its SnapServer® and SnapScale® on-premise storage solutions. The campaign entices them to augment their existing solutions with Sphere 3D’s SnapCLOUD™ – a cloud-based data storage product which is available from the Microsoft Azure Marketplace. The campaign has already resulted in over 100 SnapCLOUD customer deployments, meeting 40% of the target goal for the original 90-day period.

“This effort is designed to galvanize the inter-relationships of the various brands within the Sphere3D portfolio. We believe we will continue to gain traction through vertical integration of our distinctive capabilities that are designed to catalyze adoption of our products,” said Eric Kelly, CEO of Sphere 3D. “Many of these same loyal SnapServer and SnapScale customers have also begun looking at our G-Series Cloud, application containerization solution, powered by Glassware 2.0™, which is also available in the Microsoft Azure Marketplace.”

“My organization has been very pleased with the SnapServer product line and I view it as a trusted brand for reliability, data protection, and enterprise-grade performance,” said Macon Barham, owner of a leading national insurance agency, based in Peachtree City, GA. “When we learned about the SnapCLOUD solution last month, with its ability to provision our unstructured data in minutes within the Microsoft Azure Cloud Marketplace, it was an easy decision to help round out our data storage infrastructure.” He continued by stating, “I really like how the cloud approach allows me to control expenses by paying only for what we use; and if we need more we can quickly increase our capacity without taking on the IT expense or burden of build out and technical support.”

Sphere 3D has a large customer base of SnapServer users, consisting of both Small and Medium-sized Business (SMBs), as well as large enterprises, that are seeking to augment their on-premise storage solutions with a hybrid cloud infrastructure. The SnapCLOUD offering in the Microsoft Azure Marketplace allows customers to easily deploy a cloud-based solution while recognizing the great benefits of flexibility, load balancing and security offered by Microsoft Azure.

For a trial of SnapCLOUD from Microsoft Azure, go to https://azure.microsoft.com/en-us/marketplace/partners/sphere3d/snapcloud-standard/.

About SnapCLOUD

SnapCLOUD™ is a virtual storage platform based on Sphere 3D’s SnapServer® on-premise data storage operating system, which has been installed by 300,000 plus customers worldwide. SnapCLOUD brings the simplicity of deploying enterprise-grade data storage in minutes to meet unplanned business growth needs. The storage offering is unique in its ability to unify data manageability, access control and replication between the physical data center and the public cloud, because it is a true hybrid cloud architecture. SnapCLOUD delivers the following benefits:

• Users can create a high performance and resilient virtual environment in minutes, using servers, storage and networking from the Microsoft Azure Marketplace. On top of this, customers only pay for what they use.
• Users get secure data access anywhere and on any device. Built-in sync and share functionality enables users and devices to share data directly from SnapCLOUD in conformance with business policies.
• Users can centrally manage and monitor their on-premise physical data center and their data in the cloud, allowing data management across the organization to be the same everywhere.

About Sphere 3D

Sphere 3D Corp. (NASDAQ: ANY) delivers containerization and virtualization technologies along with data management products that enable workload-optimized solutions. We achieve this through a combination of containerized applications, virtual desktops, virtual storage and physical hyper-converged platforms. Sphere 3D’s value proposition is simple and direct—we allow organizations to deploy a combination of public, private or hybrid cloud strategies while backing them up with state of the art storage solutions. Sphere 3D, along with its wholly-owned subsidiariesOverland Storage andTandberg Data, has a strong portfolio of brands includingGlassware 2.0™,SnapCLOUD™, SnapScale®, SnapServer®,V3, RDX®, and NEO®. For more information, visit www.sphere3d.com.

# # #

Media Contacts:
Eileen Elam
408-283-4734
media.relations@sphere3d.com

Nick Foot
BWW Communications
+44-1491-636393
Nick.foot@bwwcomms.com

Investor Contact:
Blueshirt Group
Michael Bishop
415-217-4968
mike@blueshirtgroup.com

Safe Harbor Statement

This press release may contain forward-looking statements that involve risks, uncertainties, and assumptions that are difficult to predict. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties including, without limitation, unforeseen changes in the course of Sphere 3D’s business or the business of its wholly-owned subsidiaries, including, without limitation, Overland Storage and Tandberg Data;; the level of success of our collaborations and business partnerships; possible actions by customers, partners, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in Sphere 3D’s periodic reports contained in our Annual Information Form and other filings with Canadian securities regulators (www.sedar.com) and in prior periodic reports filed with the United States Securities and Exchange Commission (www.sec.gov). Sphere 3D undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.